Physician profile
Nasser A Chaudhry
NPI 1134108442
$11,413.03
in general payments reported to CMS, 2019-2025
40 companies · $734 in 2025
The $734 reported for 2025 was more than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,970 · 2020: $1,853 · 2021: $2,504 · 2022: $1,887 · 2023: $1,500 · 2024: $965 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,190 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,189.89 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,730.33 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $1,214.33 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $1,079.60 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $956.12 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $811.21 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $762.50 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $749.79 | 2019-2025 | Watchman Flx, Watchman Access System |
| Pfizer INC. | $650.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $571.08 | 2021-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $347.43 | 2021-2025 | |
| Esperion Therapeutics, INC. | $341.71 | 2020-2024 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $325.03 | 2019-2025 | Lifevest |
| Atricure, INC. | $279.54 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $200.46 | 2019-2023 | |
| Impulse Dynamics (USA) INC. | $194.22 | 2021-2024 | Optimizer, Optimizer |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $161.01 | 2021-2023 | Zio Xt Patch |
| W. L. Gore & Associates, INC. | $145.44 | 2019-2021 | |
| Heartflow, INC. | $125.29 | 2022 | |
| Abbott Laboratories | $122.59 | 2020 | |
| Abiomed | $101.82 | 2024-2025 | Impella |
| Regeneron Healthcare Solutions, INC. | $59.85 | 2019-2024 | Evkeeza |
| Amarin Pharma, INC. | $55.19 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $50.53 | 2024 | Arcalyst |
| Novo Nordisk INC | $49.40 | 2025 | Wegovy |
| Edwards Lifesciences Corporation | $38.48 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Scpharmaceuticals INC. | $37.82 | 2024-2025 | |
| Angiodynamics, INC. | $36.38 | 2023 | Venacure 1470 Pro |
| Kowa Pharmaceuticals America, INC. | $28.89 | 2019-2021 | |
| Inari Medical, INC. | $26.47 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Lexicon Pharmaceuticals, INC. | $24.59 | 2023 | Inpefa |
| Cvrx, INC. | $22.18 | 2024 | Barostim Neo System |
| Vifor Pharma, INC. | $17.76 | 2019 | |
| Smith+Nephew, INC. | $16.82 | 2021 | |
| Daiichi Sankyo INC. | $16.19 | 2023 | Injectafer |
| Astellas Pharma US INC | $13.91 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.20 | 2019 | |
| Gilead Sciences, INC. | $12.89 | 2019 | |
| Althera Pharmaceuticals LLC | $12.04 | 2021 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasser Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.